Aspirin for primary prevention: do potential benefits outweigh the risks?

被引：0
|
作者：
Shakib, S. [1 ]
机构：
[1] Royal Adelaide Hosp, Dept Clin Pharmacol, Adelaide, SA 5000, Australia
来源：
INTERNAL MEDICINE JOURNAL | 2009年 / 39卷 / 06期
关键词：
LOW-DOSE ASPIRIN; LONG-TERM USE; COLORECTAL-CANCER; CARDIOVASCULAR-DISEASE; RANDOMIZED-TRIAL; METAANALYSIS; EVENTS; WOMEN; CHEMOPREVENTION; COMPLICATIONS;
D O I：
10.1111/j.1445-5994.2008.01888.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The role of aspirin for primary prevention in healthy individuals has been the subject of clinical trials for more than a quarter of a century. Because of this evidence, or sometimes despite it, many individuals self-administer aspirin to prevent cardiovascular events. This article reviews the published work for aspirin in primary prevention of cardiovascular and malignant diseases and considers whether aspirin would be approved by regulatory authorities for this use if it were to be marketed for this indication today.
引用
收藏
页码：401 / 407
页数：7
相关论文
共 50 条
12345